Download Files:
Puromycin (dihydrochloride)
$32 – $240
Products Details
Product Description
– Puromycin dihydrochloride (CL13900 dihydrochloride), an aminonucleoside antibiotic, inhibits protein synthesis[1].
Web ID
– HY-B1743A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C22H31Cl2N7O5
Citations
– Acta Pharmacol Sin. 2023 Feb 20.|Adv Mater. 2022 Oct 20;e2206793.|Aging. 2020 Sep 14;12(17):17122-17136.|Aging. 2021 Jun 8;13(11):14892-14909.|Am J Cancer Res. 2023 May 15;13(5):1718-1743.|Am J Cancer Res. 2023 Sep 15;13(9):4222-4234.|Am J Transl Res. 2021 Apr 15;13(4):2331-2349.|Am J Transl Res. 2021 May 15;13(5):4360-4375.|Anal Biochem. 2021 Aug 29;114357.|Antioxid Redox Signal. 2022 Jun 16.|Antioxidants (Basel). 2023 Aug 18;12(8):1634.|Arch Biochem Biophys. 2023 May 19;109642.|Autophagy. 2021 Mar 25;1-19.|Bioact Mater. 12 November 2021.|Biochem Biophys Res Commun. 1 January 2022, Pages 34-41.|Biochem Biophys Res Commun. 2021 Oct 5;580:48-55.|Biochem Biophys Res Commun. 6 August 2022.|Biochem Pharmacol. 2020 Apr;174:113776.|Biodes Manuf. 03 March 2022.|Biomed Pharmacother. 2020 Jan;121:109578.|bioRxiv. 2023 Mar 31.|bioRxiv. 2023 Oct 4.|bioRxiv. April 11, 2022.|BMC Cancer. 2018 Feb 13;18(1):182. |Bull Cancer. 2023 Feb 28;S0007-4551(23)00083-8.|Cancer Commun (Lond). 2022 Nov 9.|Cancer Immunol Res. 2023 Feb 22;CIR-22-0658.|Cancer Invest. 2021 Mar 8;1-34.|Cancer Lett. 2020 Nov 1;492:162-173.|Cancer Lett. 2021 Apr 29;S0304-3835(21)00180-4.|Cancer Lett. 2021 Jul 30;518:266-277.|Cancer Manag Res. 2021 Nov 30;13:8915-8928.|Cancer Med. 2019 Oct;8(13):5903-5915.|Cancer Res. 2023 Apr 16;CAN-22-3059.|Cell Commun Signal. 2022 Jun 15;20(1):87.|Cell Death Dis. 2020 Dec 2;11(12):1032.|Cell Death Dis. 2021 Oct 14;12(10):944.|Cell Death Dis. 2021 Sep 9;12(9):842.|Cell Death Dis. 2022 Apr 18;13(4):360.|Cell Death Dis. 2023 Feb 11;14(2):107.|Cell Death Dis. 2023 Nov 25;14(11):765.|Cell Death Dis. 2023 Oct 6;14(10):653.|Cell Death Dis. 2019 Nov 21;10(12):879. |Cell Death Discov. 2021 Aug 30;7(1):226.|Cell Death Discov. 2021 May 1;7(1):89.|Cell Death Discov. 2022 Apr 23;8(1):222.|Cell Death Discov. 2022 Dec 16;8(1):493.|Cell Death Discov. 2022 Feb 22;8(1):77.|Cell Death Discov. 2022 Oct 28;8(1):432.|Cell Signal. 2020, 109878.|Clin Epigenetics. 2022 Dec 2;14(1):164.|Clin Transl Oncol. 2021 Apr 7.|Clin Transl Oncol. 2022 Dec 13.|Commun Biol. 2022 Aug 30;5(1):887.|Dig Liver Dis. 2022 Dec 29;S1590-8658(22)00827-1.|Dis Markers. 2022 Sep 23;2022:8402116.|DNA Cell Biol. 2022 Apr;41(4):447-455.|EMBO Rep. 2021 Jun 23;e52205.|Environ Toxicol. 2023 Mar 15.|Environ Toxicol. 2023 Oct 4.|Exp Cell Res. 2023 Apr 11;427(1):113598.|Exp Cell Res. 2023 Apr 24;113613.|Exp Mol Med. 2022 Jul;54(7):890-905.|Exp Mol Pathol. 2021 Oct 5;104704.|F1000Research. 03 Aug 2022.|Front Oncol. 21 April 2021.|Genes (Basel). 2022, 13(10), 1760.|Heliyon. 2022 Dec 6;8(12):e12118.|Heliyon. 2023 Aug 9.|Heliyon. 2023 Nov 15.|Int Immunopharmacol. 2023 Jul 15;122:110616.|Int J Biol Macromol. 2023 Apr 17;124476.|Int J Mol Sci. 2023 Sep 23, 24(19), 14476.|Int J Oncol. 2023 Apr;62(4):45.|J Appl Toxicol. 2023 Apr 14.|J Biol Chem. 2021 Feb 10;296:100413.|J Biol Chem. 2021 Jan 8;100276.|J Biol Chem. 2023 Jan 28.|J Cancer. 2023 May 8; 14(8): 1309-1320.|J Cell Mol Med. 2023 Mar 14.|J Ethnopharmacol. 2023 Apr 3;116446.|J Exp Clin Cancer Res. 2021 Nov 25;40(1):373.|J Exp Clin Cancer Res. 2022 Mar 28;41(1):111.|J Exp Clin Cancer Res. 2023 Nov 6;42(1):294.|J Exp Clin Cancer Res. 2023 Oct 3;42(1):258.|J Hematol Oncol. 2021 Jul 10;14(1):109.|Life Sci. 2022 Jan 19;293:120320.|Mbio. 2023 Oct 26:e0168823.|Mol Cancer. 2019 Aug 22;18(1):127. |Mol Carcinog. 2023 Jun 28.|Mol Cell Biochem. 2021 Jun;476(6):2503-2512.|Mol Cell. 2023 Nov 20:S1097-2765(23)00914-0.|Mol Cell. 2023 Nov 24:S1097-2765(23)00911-5.|Molecules. 2023, 28(3), 1103.|Nat Commun. 2019 Dec 2;10(1):5492. |Nat Commun. 2022 Mar 10;13(1):1248.|Neuro Oncol. 2022 Jun 20;noac156.|Oncogene. 2021 Nov 29.|Oncogene. 2023 Aug 18.|Oncol Rep. 2021 Feb;45(2):523-534.|Oncol Rep. 2023 Aug;50(2):148.|Oncotargets Ther. 2020 Sep 30;13:9701-9719.|Peer J Prints. June 6, 2022.|Phytomedicine. 2023 Mar 15;114:154769.|Poult Sci. 2023 Jul 14, 102864.|Reprod Biomed Online. 2023 Jun 23.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Apr 17.|Research Square Preprint. 2023 Nov 25.|Research Square Preprint. 2023 Sep 27.|Research Square Print. 2022 Aug.|Research Square Print. 2023 Mar 15.|Sci Rep. 2022 Nov 5;12(1):18809.|Signal Transduct Target Ther. 2022 Feb 28;7(1):54.|SSRN. 2021 Jun.|STAR Protoc. 2022 Apr 13;3(2):101296.|STAR Protoc. 2022 Nov 2;3(4):101808.|Stem Cell Rev Rep. 2023 Jan 11.|Stem Cells Int. 2020 Aug 29;2020:8860185. |Vet Microbiol. 2023 Jun 28;284:109823.|Virus Res. 2023 Apr 15;328:199086.|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Adv Funct Mater. 2019, 1808556.|Biochem Pharmacol. 2017 Mar 15;128:12-25.|bioRxiv. 2023 Jun 17.|Cancer Cell Int. 2019 Jul 24;19:192. |Cancer Immunol Res. 2023 May 2;CIR-22-0814.|Cell Signal. 2019 Mar 5;58:119-130. |Evid Based Complement Alternat Med. 2019 Mar 24;2019:1635837.|Hepatology. 2021 Apr;73(4):1327-1345.|Int J Oncol. 2020 Jul;57(1):161-170.|J Cell Mol Med. 2019 Feb;23(2):954-966.|J Exp Clin Cancer Res. 2016 Nov 7;35(1):173. |Onco Targets Ther. 2019 Jan 25;12:835-848. |PLoS One. 2017 Oct 10;12(10):e0185565.|R Soc Open Sci. 2018 Aug 29;5(8):172376.|Theranostics. 2020 May 16;10(14):6483-6499. |Theranostics. 2021 Mar 5;11(10):5045-5060.|Toxicol Appl Pharmacol. 2019 Sep 1;378:114625. |Transl Res. 2023 Apr 28;S1931-5244(23)00072-5.
References
– [1]Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92.|[2]Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82.|[3]Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7.
CAS Number
– 58-58-2
Molecular Weight
– 544.43
Compound Purity
– 99.89
SMILES
– OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C3N=CN=C4N(C)C)O1)O.[H]Cl.[H]Cl
Clinical Information
– Launched
Research Area
– Infection
Solubility
– DMSO : 50 mg/mL (ultrasonic)|Ethanol : 5 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 50 mg/mL (ultrasonic;warming)|Methanol : 250 mg/mL (ultrasonic)
Target
– Antibiotic;Bacterial;Parasite
Isoform
– Aminoglycoside
Pathway
– Anti-infection
Product type
– Natural Products
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
